Wait, That's the Reasoning Behind Minnesota's Anti-ICE Lawsuit Against the Federal Governm...
A CNBC Host Delivered One Remark That Wrecked a Dem Senator's Entire Narrative...
A Reporter in the WH Press Pool Tried to Hide Who She Worked...
Chevron Showdown: Supreme Court Weighs Energy Lawfare and Rogue Courts
Why Free Speech Scares the Hell Out of the Left
A Tough Week for PBS As It Struggles With Defunding – and Struggles...
Mark Ruffalo and His Hollywood Comrades Turned Golden Globes Into Anti-ICE Protest
Trump Says the US is 'Screwed' if Supreme Court Strikes Down His Liberation...
Radio Host Resigns After Calling for the Assassination of Vice President JD Vance
Elizabeth Warren Calls on Democrats to Double Down on Progressive Economics
Mark Kelly Files Lawsuit Against Pete Hegseth Following ‘Seditious Six' Censure Effort
Trump Signals Exxon Could Be Shut Out of Venezuela Oil Opportunities As the...
Progressive Squad Member Calls Trump a ‘Dictator,’ Demands ICE Be Abolished Following Deat...
Trump Imposes 'Immediate' Tariffs on Iranian Trade Partners As Anti-Regime Protests Grow
Meta Taps Trump Ally for High Level Job
Tipsheet
Premium

Surprise, Surprise: Look Where Birx Just Landed a New Job

AP Photo/Alex Brandon

In a bombshell video exposé released by Project Veritas earlier this year, a Pfizer director of research and development spoke openly about the "revolving door" between government and pharmaceutical companies—an arrangement that's "pretty good for the industry but bad for everyone else in America." 

When asked to clarify, he told the undercover PV journalist, "Because if the regulators, who review our drugs, you know that once they stop being a regulator, they want to go work for the company, they are not going to be as harsh on the company where they're getting their job."

One look at where former top officials went after leaving the government confirms this.

Former FDA commissioner Mark McClellan went over to Johnson & Johnson, another former FDA commissioner, Scott Gottlieb, is now at Pfizer, while former FDA commissioner Stephen Hahn is currently in a chief medical officer role at Flagship Pioneering, the investor behind Moderna. And these are just a few examples. 

Most recently, former White House COVID adviser Dr. Deborah Birx, who worked in the federal government for decades, has been added to this "revolving door" list. 

Earlier this month, Birx was appointed CEO of Armata Pharmaceuticals, a California-based biotech company focused on the development of bacteriophage therapeutics that help treat antibiotic-resistant bacterial infections.

"I am thrilled to join Armata at this pivotal time in the Company's development," Birx said in a statement. "I'm impressed with the scientific platform's quality and the team's commitment to introducing innovative treatment options for patients suffering from serious bacterial infections. I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation. The recent investment enables the advancement of AP‐PA02 and AP‐SA02 in Phase 2 clinical trials." 


Recommended

Trending on Townhall Videos